# APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

> **NCT04785196** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 95 (estimated)

## Conditions studied

- Liposarcoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** APG-115
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04785196
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-26
- **Primary completion:** 2026-04
- **Final completion:** 2027-01
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2025-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04785196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04785196, "APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT04785196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*